Contrasting Prime Medicine (NYSE:PRME) & ZIVO Bioscience (NASDAQ:ZIVO)

ZIVO Bioscience (NASDAQ:ZIVO) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Insider and Institutional Ownership

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares ZIVO Bioscience and Prime Medicine”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15,850.00	2,099.28	-$7.78 million	($2.18)	-3.84
Prime Medicine	$5.98 million	104.19	-$198.13 million	($1.44)	-2.40

ZIVO Bioscience has higher earnings, but lower revenue than Prime Medicine. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ZIVO Bioscience has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.7, suggesting that its stock price is 170% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for ZIVO Bioscience and Prime Medicine, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0	0	0	0	0.00
Prime Medicine	0	3	4	0	2.57

Prime Medicine has a consensus price target of $7.21, suggesting a potential upside of 108.94%. Given Prime Medicine’s stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than ZIVO Bioscience.

Profitability

This table compares ZIVO Bioscience and Prime Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Prime Medicine	N/A	-107.87%	-74.97%

Summary

Prime Medicine beats ZIVO Bioscience on 9 of the 13 factors compared between the two stocks.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.